HC Wainwright Reaffirms Buy Rating for Pyxis Oncology (NASDAQ:PYXS)

Pyxis Oncology (NASDAQ:PYXS)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $7.00 price target on the stock. HC Wainwright’s target price suggests a potential upside of 268.42% from the stock’s previous close.

A number of other brokerages have also issued reports on PYXS. Royal Bank of Canada reissued an “outperform” rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Thursday, September 19th. William Blair lowered Pyxis Oncology from an “outperform” rating to a “market perform” rating in a report on Thursday. Stephens initiated coverage on shares of Pyxis Oncology in a research report on Friday, November 8th. They issued an “overweight” rating and a $13.00 target price for the company. Finally, Stifel Nicolaus assumed coverage on shares of Pyxis Oncology in a research report on Thursday, August 8th. They set a “buy” rating and a $10.00 price target on the stock. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Pyxis Oncology Stock Down 9.5 %

Shares of NASDAQ:PYXS opened at $1.90 on Thursday. The company’s 50-day moving average price is $3.64 and its 200 day moving average price is $3.62. The company has a market cap of $112.99 million, a PE ratio of -1.84 and a beta of 1.27. Pyxis Oncology has a fifty-two week low of $1.35 and a fifty-two week high of $6.85.

Institutional Trading of Pyxis Oncology

A number of hedge funds and other institutional investors have recently made changes to their positions in PYXS. Barclays PLC raised its position in shares of Pyxis Oncology by 275.0% during the third quarter. Barclays PLC now owns 64,089 shares of the company’s stock worth $235,000 after purchasing an additional 46,997 shares during the period. Geode Capital Management LLC raised its holdings in Pyxis Oncology by 5.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,084,727 shares of the company’s stock worth $3,982,000 after buying an additional 57,016 shares during the period. Public Employees Retirement System of Ohio purchased a new stake in Pyxis Oncology during the third quarter valued at about $107,000. XTX Topco Ltd raised its holdings in shares of Pyxis Oncology by 133.6% during the third quarter. XTX Topco Ltd now owns 84,771 shares of the company’s stock valued at $311,000 after acquiring an additional 48,481 shares during the period. Finally, Jane Street Group LLC lifted its position in shares of Pyxis Oncology by 40.8% in the 3rd quarter. Jane Street Group LLC now owns 49,558 shares of the company’s stock valued at $182,000 after acquiring an additional 14,349 shares in the last quarter. 39.09% of the stock is currently owned by institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.